As previously reported, Wells Fargo analyst Derek Archila upgraded Immunovant (IMVT) to Overweight from Equal Weight with a price target of $27, up from $10. The analyst expects pos read through from Argenx (ARGX) CIDP and Johnson & Johnson (JNJ) RA trials to benefit shares. Second half of 2023 Phase 1 safety catalyst for IMVT-1402 could offer 2-3-times upside, in his view.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IMVT:
- Immunovant upgraded to Overweight from Equal Weight at Wells Fargo
- Roivant’s upcoming data readouts could move stock higher, says Cantor Fitzgerald
- Immunovant price target raised to $17 from $16 at H.C. Wainwright
- Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
